VDA 1102

Drug Profile

VDA 1102

Alternative Names: VDA-1102

Latest Information Update: 19 Oct 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator VidacPharma
  • Class Antineoplastics; Skin disorder therapies; Small molecules
  • Mechanism of Action Hexokinase inhibitors; Keratinocyte modulators; Voltage-dependent anion channel modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Actinic keratosis
  • Preclinical Cutaneous T cell lymphoma; Solid tumours; Squamous cell cancer

Most Recent Events

  • 12 Oct 2017 Efficacy and adverse events data from a phase IIa trial in Actinic keratosis released by VidacPharma
  • 12 Oct 2017 VidacPharma plans a phase IIb trial for Actinitic keratosis in 2018
  • 01 May 2017 VidacPharma completes a phase II trial in Actinic keratosis in USA and Israel (NCT02844777)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top